恒瑞医药再度借船出海:与默沙东达成授权合作,获2亿美元首付款

第一财经
26 Mar

在“双艾”组合疗法闯关美国FDA遇挫后,恒瑞医药(600276.SH)在出海上放出“大招”。  3月25日晚间,恒瑞医药宣布,将公司的脂蛋白(a)[Lp(a)]口服小分子项目(包括名为HRS-5346的先导化合物)有偿许可给默沙东,后者将获得HRS-5346在大中华地区以外的全球范围内开发、生产和商业化的独家权利。  HRS-5346是一种在研的Lp(a)口服小分子抑制剂,目前正在中国进行二期...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10